AC
NWBO

Alexandria Capital’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Alexandria Capital’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-600
Closed – – 656
2016
Q3 		$0 Hold
600
– – ﹤0.01% 680
2016
Q2 		$0 Hold
600
– – ﹤0.01% 691
2016
Q1 		$1K Hold
600
– – ﹤0.01% 592
2015
Q4 		$2K Hold
600
– – ﹤0.01% 612
2015
Q3 		$4K Hold
600
– – ﹤0.01% 515
2015
Q2 		$6K Hold
600
– – ﹤0.01% 487
2015
Q1 		$4K Hold
600
– – ﹤0.01% 530
2014
Q4 		$3K Hold
600
– – ﹤0.01% 523
2014
Q3 		$3K Hold
600
– – ﹤0.01% 512
2014
Q2 		$4K Hold
600
– – ﹤0.01% 488
2014
Q1 		$4K Hold
600
– – ﹤0.01% 499
2013
Q4 		$2K Buy
+600
New +$2.32K ﹤0.01% 575

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Alexandria Capital's NWBO Position: Q4 2016 in Review

Alexandria Capital sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 600 shares.

Alexandria Capital first reported a position in NWBO in Q4 2013 and held it in 12 quarters. The position peaked at $6K in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Alexandria Capital reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Alexandria Capital sold 600 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016.
  • Alexandria Capital first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 12 quarters.
  • Alexandria Capital's Northwest Biotherapeutics, Inc. Common stock position peaked at $6K in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Alexandria Capital's 13F filing for Q4 2016, filed 3 Feb 2017.